Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

C4 Imaging signs Sirius MRI Marker loading services agreement with AnazaoHealth

C4 Imaging has announced the signing of a loading services agreement for it's first product, the Sirius MRI Marker, with AnazaoHealth.

The novel positive-signal, MRI marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant magnetic resonance imaging procedure.

C4 Imaging will partner with AnazaoHealth, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius MRI Marker alongside seeds into brachytherapy strands and needles according a physician prescription tailored to each individual patient.

C4 Imaging president and CEO Andrew Bright noted that AnazaoHealth has a long-standing reputation for quality and service to the prescription-loaded prostate brachytherapy market.

"We are delighted to partner with them, allowing broad access to our Sirius™ MRI Marker for prostate brachytherapy physicians and seed vendors alike," Bright added.

AnazaoHealth president and COO Chris A Arnette noted that while C4 Imaging is a new entrant into the US prostate brachytherapy market the company’s management team is highly experienced in this area.

"We are excited to partner with them as they introduce the Sirius™ MRI Marker. Sirius™ has the potential to revolutionize prostate brachytherapy; with improved MRI based post-implant imaging leading to further increases in the quality of this highly-effective and cost-effective treatment option," Arnette added.